SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (5367)1/9/2002 11:29:10 AM
From: Ian@SI  Read Replies (2) | Respond to of 52153
 
IMCL valuation: Seems to me that the latest gem will guarantee that the class action piranhas come out of the woodwork.

Whole story for subscribers at: interactive.wsj.com

ImClone Shares Sold Prior to FDA's Move

ImClone Systems' chief operating officer disposed of a $50 million
stake in the biopharmaceuticals developer just weeks before it
disclosed the FDA's rejection of its application to sell Erbitux, a
colorectal-cancer drug.



To: Icebrg who wrote (5367)1/9/2002 11:39:59 AM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
Ice,

You look correct to me - this MEDX trial does indeed seem to be a combo of unapproved products. Personally I believe this is necessary in some situations, so I'm pleased the FDA let them do it.

It still remains to be seen at approval time if the FDA will start grumbling about what effect each component is having and demanding additional individual trials of each component.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News